Anastrozole Increases Predicted Adult Height of Short Adolescent Males Treated with Growth Hormone: A Randomized, Placebo-Controlled, Multicenter Trial for One to Three Years
Open Access
- 1 March 2008
- journal article
- research article
- Published by The Endocrine Society in Journal of Clinical Endocrinology & Metabolism
- Vol. 93 (3), 823-831
- https://doi.org/10.1210/jc.2007-1559
Abstract
Context: The process of epiphyseal fusion during puberty is regulated by estrogen, even in males. Objective: Our objective was to investigate whether anastrozole, a potent aromatase inhibitor, could delay bone age acceleration and increase predicted adult height in adolescent boys with GH deficiency. Methods: Fifty-two adolescent males with GH deficiency treated with GH were randomized to cotreatment with anastrozole or placebo daily for up to 36 months. Results: Fifty subjects completed 12 months, 41 completed 24 months, and 28 completed 36 months. Linear growth was comparable between groups; however, there was a significantly slower increase in bone age advancement from baseline in the anastrozole group vs. placebo group after 2 yr (+1.8 ± 0.1 vs. +2.7 ± 0.1 yr, P < 0.0001) and after 3 yr (+2.5 ± 0.2 vs. +4.1 ± 0.1 yr, P < 0.0001). This resulted in a net increase in predicted adult height of +4.5 ± 1.2 cm in the anastrozole group at 24 months and +6.7 ± 1.4 cm at 36 months as compared with a 1-cm gain at both time points in the placebo group. Estradiol and estrone concentrations increased less in the anastrozole group compared with placebo group. All boys on the aromatase inhibitor had normal tempo of virilization. Safety data, including glucose, and plasma lipid concentrations were comparable between groups. Conclusions: Anastrozole increases adult height potential of adolescent boys on GH therapy while maintaining normal pubertal progression after 2–3 yr. This treatment offers an alternative in promoting growth in GH-deficient boys in puberty. Long-term follow up is needed to elucidate fully the safety and efficacy of this approach.This publication has 49 references indexed in Scilit:
- Treatment of familial male-limited precocious puberty with bicalutamide and anastrozoleThe Journal of Pediatrics, 2006
- A brief review of the addition of gonadotropin-releasing hormone agonists (GnRH-Ag) to growth hormone (GH) treatment of children with idiopathic growth hormone deficiency: Previously published studies from AmericaMolecular and Cellular Endocrinology, 2006
- Treatment with the aromatase inhibitor letrozole during adolescence increases near‐final height in boys with constitutional delay of pubertyClinical Endocrinology, 2006
- Effect of growth hormone therapy and puberty on bone and body composition in children with idiopathic short stature and growth hormone deficiencyBone, 2005
- A specific aromatase inhibitor and potential increase in adult height in boys with delayed puberty: a randomised controlled trialThe Lancet, 2001
- Profound Hypogonadism Has Significant Negative Effects on Calcium Balance in Males: A Calcium Kinetic StudyJournal of Bone and Mineral Research, 1999
- Effect of Testosterone and Estradiol in a Man with Aromatase DeficiencyThe New England Journal of Medicine, 1997
- Height prognosis of children with true precocious puberty and growth hormone deficiency: Effect of combination therapy with gonadotropin releasing hormone agonist and growth hormoneThe Journal of Pediatrics, 1992
- Adult height in boys and girls with untreated short stature and constitutional delay of growth and puberty: Accuracy of five different methods of height predictionThe Journal of Pediatrics, 1990
- Bayley-Pinneau, Roche-Wainer-Thissen, and Tanner height predictions in normal children and in patients with various patholgoic conditionsThe Journal of Pediatrics, 1978